At Loxo Oncology at Lilly, our goal is to create an industry leading pipeline consisting of medicines with the potential to make meaningful differences in the lives of cancer patients. We are actively seeking partnerships with world-class industry and academic collaborators in order to optimize and accelerate the development of new cancer medicines.
We believe that good drugs can come from anywhere and are actively looking for opportunities across discovery and development that align with our areas of interest.
We are focused on the development of medicines with unequivocal activity early in the drug development process, which have the potential for outsized and differentiated effects for patients. Our team is agnostic to the biologic basis of our programs, so long as we have high conviction in the science and believe they will matter for patients.
While not all of our programs rely on genomic profiling, we firmly believe that genomic testing is the cornerstone of precision medicine in oncology and key to realizing the full potential of many of our treatments. We have formed meaningful collaborations with pathologists at leading academic medical centers and partnerships with diagnostics companies in support of our programs with the goal of pursuing multiple different diagnostic strategies across our portfolio. We work broadly to partner with diagnostic stakeholders across a range of activities: enrollment support, assay validation, companion diagnostic development and implementation of high-quality testing within the clinical laboratory.
Loxo Oncology at Lilly supports third-party research that is aimed at furthering scientific knowledge and understanding in oncology. Loxo Oncology at Lilly will assess proposals for providing study drug and/or financial support for Investigator-Initiated Research based on scientific merit and strategic fit with our areas of research interest.
Please use the below form to submit your idea for a study. The Loxo Oncology at Lilly team will review your submission and be in touch: